Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
- Check22 days agoChange DetectedThe website has been updated with new additions including dates from September 2024 and a new revision v2.11.0, while previous notices and older revisions have been removed.SummaryDifference0.4%
- Check30 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.2%
- Check44 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.0%
- Check65 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2.SummaryDifference0.0%
- Check85 days agoChange DetectedThe website has removed the 'Last Update Posted (Estimated)' and now features a definitive 'Last Update Posted' section.SummaryDifference0.0%
Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.